Treatment attrition and outcomes of myeloma patients in Finland: a real-world study.
5 affiliations
- 1Hematology and Stem Cell Transplant Unit, Wellbeing Services County of Southwest Finland, Turku University Hospital, Turku, Finland.
- 2Johnson & Johnson, Espoo, Finland.
- 3Medaffcon Oy, Espoo, Finland.
- 4Department of Medicine, Wellbeing Services County of Pirkanmaa, Tampere University Hospital, Tampere, Finland.
- 5Department of Medicine, Wellbeing Services County of North Savo, Kuopio University Hospital, Kuopio, Finland. [email protected].
Abstract
Background and purpose
Relapses, need for further treatment lines and significant treatment attrition are typical for multiple myeloma (MM). This retrospective study investigates attrition and outcomes among MM patients in Finland. Patient, material and methods: Study included all adult MM patients (n = 1733) diagnosed and treated in four hospital districts in Finland in 2013-2022. Data were collected from hospital data lakes, Statistics Finland and Social Insurance Institution. Treatment attrition was defined as death before next treatment line.Results
By the end of follow-up 31% of patients without stem cell transplantation (non-SCT) had died before initiation of second line treatment (2L), compared with 5% of stem-cell transplant (SCT) patients. The factors associating with this early attrition in the non-SCT cohort were older age (over 75 years), higher comorbidity burden, International Staging System (ISS), and (R)-ISS scores (p < 0.001). Furthermore, non-SCT patients were more likely administered less intensive therapy during 1L (p < 0.001). During the first 6 months post diagnosis in the non-SCT cohort, the most common immediate cause of death was MM. Also, during later stages MM was responsible for 54% of deaths in the non-SCT and 68% in the SCT cohorts whereas infections were linked principally with early deaths before 2L treatment.Interpretation
This study highlights significant treatment attrition across disease course and also early mortality especially in the non-SCT cohort resulting primarily from progressive MM or infections. The findings underscore the need for more tolerable and effective anti-myeloma treatments in earlier course of the disease to enhance patient survival.
Related
- Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy
- Treatment Patterns, Treatment Response, and Survival Outcomes in Patients with Multiple Myeloma: A Single-Center Real-World Study
- Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium
- Pretreatment Attrition, Treatment Delay and Treatment Outcome in Drug-Resistant Tuberculosis: A Mixed-Methods Cohort Study in Public and Private Hospitals in Indonesia
- Identification and operative vs. conservative vs. no treatment trial of breastfeeding-impeding lingual frenulum in newborn infants (LINNE): protocol for a randomized controlled trial (RCT) embedded in a prospective observational cohort study in Northern Finland
BibTeX
@article{putkonen2026treatment,
title = {{Treatment attrition and outcomes of myeloma patients in Finland: a real-world study.}},
author = {Mervi Putkonen and Katja Närhi and Johanna Vikkula and Riikka Mattila and Marika Waltari and Jonna Eeva and Anu Partanen},
journal = {Acta oncologica (Stockholm, Sweden)},
year = {2026},
month = oct,
doi = {10.2340/1651-226x.2026.46473},
url = {https://europepmc.org/article/MED/42899458},
note = {CC BY},
}
RIS
TY - JOUR
TI - Treatment attrition and outcomes of myeloma patients in Finland: a real-world study.
AU - Mervi Putkonen
AU - Katja Närhi
AU - Johanna Vikkula
AU - Riikka Mattila
AU - Marika Waltari
AU - Jonna Eeva
AU - Anu Partanen
PY - 2026
DA - 2026/10/20
JO - Acta oncologica (Stockholm, Sweden)
DO - 10.2340/1651-226x.2026.46473
UR - https://europepmc.org/article/MED/42899458
AB - Background and purpose Relapses, need for further treatment lines and significant treatment attrition are typical for multiple myeloma (MM). This retrospective study investigates attrition and outcomes among MM patients in Finland. Patient, material and methods: Study included all adult MM patients (n = 1733) diagnosed and treated in four hospital districts in Finland in 2013-2022. Data were collected from hospital data lakes, Statistics Finland and Social Insurance Institution. Treatment attrition was defined as death before next treatment line.Results By the end of follow-up 31% of patients without stem cell transplantation (non-SCT) had died before initiation of second line treatment (2L), compared with 5% of stem-cell transplant (SCT) patients. The factors associating with this early attrition in the non-SCT cohort were older age (over 75 years), higher comorbidity burden, International Staging System (ISS), and (R)-ISS scores (p < 0.001). Furthermore, non-SCT patients were more likely administered less intensive therapy during 1L (p < 0.001). During the first 6 months post diagnosis in the non-SCT cohort, the most common immediate cause of death was MM. Also, during later stages MM was responsible for 54% of deaths in the non-SCT and 68% in the SCT cohorts whereas infections were linked principally with early deaths before 2L treatment.Interpretation This study highlights significant treatment attrition across disease course and also early mortality especially in the non-SCT cohort resulting primarily from progressive MM or infections. The findings underscore the need for more tolerable and effective anti-myeloma treatments in earlier course of the disease to enhance patient survival.
SN - 0284-186X
SN - 1651-226X
ER -